+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dengue Vaccine Market - Global Forecast 2026-2032- Product Image
Dengue Vaccine Market - Global Forecast 2026-2032- Product Image
Sale

Dengue Vaccine Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6083662
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dengue Vaccine Market is projected to reach USD 635.93 Million in 2026. It is expected to continue growing at a CAGR of 9.43%, reaching USD 1.09 Billion by 2032.

Dengue Vaccines: Executive Overview

Dengue vaccination is shaped by the disease’s expanding geographic footprint, uneven transmission intensity, climate-sensitive mosquito ecology, and the need to match products with individual and population-level risk. Public-health decisions depend on age eligibility, prior infection status where relevant, safety evidence, local epidemiology, delivery capacity, and integration with mosquito control and clinical surveillance.

How Dengue Prevention Is Being Transformed

The prevention landscape is moving from outbreak response toward more structured, risk-based immunization strategies. Health authorities are strengthening laboratory surveillance, case detection, serotype monitoring, and vaccination guidance while also improving cold-chain planning and community communication. Because vaccination does not replace vector control, effective programs increasingly combine immunization with source reduction, insecticide-management practices, personal protection, and rapid access to care for warning signs.

Artificial Intelligence and Dengue Vaccine Programs

Artificial intelligence can support dengue vaccine programs by identifying transmission patterns, improving outbreak detection, optimizing clinic and cold-chain logistics, and helping health systems target communication. Models may combine weather, mobility, mosquito, laboratory, and clinical data, but their value depends on representative datasets, transparent validation, privacy safeguards, and human oversight. AI should inform-not independently determine-eligibility, clinical decisions, or public-health prioritization.

Regional Dengue Vaccine Priorities Across Six Geographies

North America is primarily focused on travel-related protection, surveillance, and preparedness for localized transmission. Latin America faces substantial endemic and outbreak-management needs, making product suitability, prior-infection considerations, equitable access, and integration with established immunization systems especially important. Europe emphasizes traveler guidance, imported-case surveillance, and readiness for changing vector habitats. The Middle East requires attention to travel-linked risk, health-system preparedness, and vector surveillance. Africa’s priorities include stronger disease detection, evidence generation, and delivery infrastructure in areas where dengue may be underrecognized. Asia-Pacific combines long-standing endemic transmission in several settings with diverse national policies, high population mobility, and the need to align vaccination with robust vector-control programs.

Dengue Vaccine Implications for ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN countries must coordinate across highly connected populations and varied dengue epidemiology, with emphasis on surveillance interoperability and practical delivery models. BRICS members span major endemic areas and large health systems, creating opportunities to strengthen manufacturing, evidence generation, and access while respecting national regulatory requirements. The European Union benefits from coordinated scientific and regulatory collaboration, particularly for travel and emerging local transmission. G7 countries can advance research, surveillance standards, financing, and preparedness. GCC members should focus on imported risk, migrant and traveler health, and vector monitoring. NATO members may incorporate dengue readiness into military medicine, deployment protocols, and operational health protection without treating vaccination as a substitute for broader preventive measures.

Country-Level Dengue Vaccine Considerations

Australia combines endemic risk in parts of the country with substantial travel-related exposure, requiring targeted surveillance and clear eligibility guidance. Brazil needs scalable, equitable approaches integrated with extensive vector-control and surveillance activities. Canada and the United States primarily address travel-associated risk and preparedness for localized transmission. China and India require approaches suited to large, diverse populations and regionally variable transmission. France, Germany, Italy, Spain, and the United Kingdom must address travel medicine, imported cases, and changing vector suitability, with France and Spain also monitoring local transmission risks in appropriate areas. Japan and South Korea emphasize travel-related protection, surveillance, and preparedness. Mexico requires alignment between vaccination policy, outbreak response, and established public-health infrastructure. Russia’s approach must account for travel-linked exposure, surveillance, and changing ecological conditions.

Actions for Leaders Strengthening Dengue Vaccine Readiness

Industry and public-health leaders should establish evidence-based eligibility and monitoring frameworks; connect vaccination with vector control, diagnostics, and clinical referral pathways; and invest in transparent communication about benefits, limitations, and adverse-event reporting. They should also strengthen temperature-controlled distribution, train frontline providers, measure uptake and completion, and use post-introduction surveillance to assess safety and program performance. Cross-border data collaboration, locally relevant clinical evidence, and procurement planning can improve resilience while keeping equity and affordability central to decision-making.

Research Methodology for the Dengue Vaccine Assessment

This executive summary uses a structured synthesis of verified public-health, regulatory, epidemiological, clinical, and immunization-policy evidence. The assessment considers dengue transmission patterns, vaccine characteristics, safety and effectiveness evidence, eligibility guidance, delivery requirements, surveillance practices, vector-control integration, and regional health-system conditions. Findings are organized across specified regions, country groups, and countries, while avoiding unsupported estimates and separating established evidence from implementation considerations. Because policies and epidemiology change, conclusions should be reviewed against current national guidance and newly published evidence.

Conclusion: Building Integrated, Evidence-Led Dengue Prevention

Dengue vaccine policy is most effective when embedded in a broader prevention system that combines appropriate immunization, reliable surveillance, vector control, clinical readiness, and clear public communication. Regional and national differences make a single universal strategy unsuitable. Leaders should therefore prioritize locally grounded evidence, equitable delivery, continuous safety monitoring, and cross-border cooperation to strengthen protection as dengue risk evolves.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Dengue Vaccine Market, by Vaccine Type
7.1. Introduction
7.2. Live Attenuated
7.3. Recombinant Subunit
8. Dengue Vaccine Market, by Dosage Form
8.1. Introduction
8.2. Multi-Dose Vial
8.3. Prefilled Syringe
8.4. Single-Dose Vial
9. Dengue Vaccine Market, by Age Group
9.1. Introduction
9.2. Adolescents
9.3. Adults
9.4. Children
10. Dengue Vaccine Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Dengue Vaccine Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Research Institutes
12. Dengue Vaccine Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Dengue Vaccine Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Dengue Vaccine Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Biological E. Limited
16.2. GeneOne Life Science
16.3. GlaxoSmithKline (GSK) plc
16.4. Johnson & Johnson Services, Inc.
16.5. Medigen Vaccine Biologics
16.6. Merck & Co. Inc.
16.7. Novartis AG
16.8. Sanofi Pasteur
16.9. Serum Institute of India
16.10. Sun Pharmaceutical Industries Ltd.
16.11. Takeda Pharmaceutical Company
16.12. Vabiotech
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Dengue Vaccine Market, Years Considered for the Study
FIGURE 2. Global Dengue Vaccine Market, Research Design
FIGURE 3. Global Dengue Vaccine Market, Research Framework
FIGURE 4. Global Dengue Vaccine Market, Data Triangulation
FIGURE 5. Global Dengue Vaccine Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Dengue Vaccine Market Size, by Vaccine Type, 2025 vs 2032 (%)
FIGURE 7. Global Dengue Vaccine Market Size, by Vaccine Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Dengue Vaccine Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 9. Global Dengue Vaccine Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Dengue Vaccine Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 11. Global Dengue Vaccine Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Dengue Vaccine Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Dengue Vaccine Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Dengue Vaccine Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Dengue Vaccine Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Dengue Vaccine Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Dengue Vaccine Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Dengue Vaccine Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Dengue Vaccine Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Dengue Vaccine Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Dengue Vaccine Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Dengue Vaccine Market Segmentation & Coverage
TABLE 2. Global Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 3. Global Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 4. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Recombinant Subunit Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Recombinant Subunit Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Recombinant Subunit Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 11. Global Multi-Dose Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Multi-Dose Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Multi-Dose Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Single-Dose Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Single-Dose Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Single-Dose Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 21. Global Adolescents Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Adolescents Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Adolescents Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Children Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Children Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Children Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 31. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 41. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Dengue Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Dengue Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 57. North America Dengue Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. North America Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 59. North America Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 60. North America Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 61. North America Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 62. North America Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 63. Latin America Dengue Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Latin America Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 65. Latin America Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 66. Latin America Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 67. Latin America Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 68. Latin America Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 69. Europe Dengue Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Europe Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 71. Europe Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 72. Europe Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 73. Europe Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. Europe Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. Middle East Dengue Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Middle East Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 77. Middle East Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 78. Middle East Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 79. Middle East Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. Middle East Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Africa Dengue Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Africa Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 83. Africa Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 84. Africa Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 85. Africa Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. Africa Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Global Dengue Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. ASEAN Dengue Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. ASEAN Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 90. ASEAN Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 91. ASEAN Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 92. ASEAN Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. ASEAN Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. GCC Dengue Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. GCC Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 96. GCC Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 97. GCC Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 98. GCC Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. GCC Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 100. European Union Dengue Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. European Union Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 102. European Union Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 103. European Union Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 104. European Union Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. European Union Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 106. BRICS Dengue Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. BRICS Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 108. BRICS Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 109. BRICS Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 110. BRICS Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. BRICS Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. G7 Dengue Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. G7 Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 114. G7 Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 115. G7 Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 116. G7 Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. G7 Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. NATO Dengue Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. NATO Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 120. NATO Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 121. NATO Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 122. NATO Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. NATO Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. Global Dengue Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. United States Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 126. United States Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 127. United States Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 128. United States Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 129. United States Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 130. United States Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. Canada Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 132. Canada Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 133. Canada Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 134. Canada Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 135. Canada Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. Canada Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. Mexico Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 138. Mexico Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 139. Mexico Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 140. Mexico Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 141. Mexico Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. Mexico Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. Brazil Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 144. Brazil Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 145. Brazil Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 146. Brazil Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 147. Brazil Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. Brazil Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 149. United Kingdom Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 150. United Kingdom Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 151. United Kingdom Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 152. United Kingdom Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 153. United Kingdom Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. United Kingdom Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. Germany Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 156. Germany Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 157. Germany Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 158. Germany Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 159. Germany Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Germany Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 161. France Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 162. France Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 163. France Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 164. France Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 165. France Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. France Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Russia Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 168. Russia Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 169. Russia Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 170. Russia Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 171. Russia Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 172. Russia Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. Italy Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 174. Italy Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 175. Italy Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 176. Italy Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 177. Italy Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. Italy Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. Spain Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 180. Spain Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 181. Spain Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 182. Spain Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 183. Spain Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. Spain Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. China Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 186. China Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 187. China Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 188. China Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 189. China Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. China Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. India Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 192. India Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 193. India Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 194. India Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 195. India Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. India Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. Japan Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 198. Japan Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 199. Japan Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 200. Japan Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 201. Japan Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. Japan Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Australia Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 204. Australia Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 205. Australia Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 206. Australia Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 207. Australia Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. Australia Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. South Korea Dengue Vaccine Market Size, 2017-2032 (USD Million)
TABLE 210. South Korea Dengue Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 211. South Korea Dengue Vaccine Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 212. South Korea Dengue Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 213. South Korea Dengue Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. South Korea Dengue Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. Global Dengue Vaccine Market Share, by Key Player, 2025
TABLE 216. Global Dengue Vaccine Market, Key Experts

Companies Mentioned

  • Biological E. Limited
  • GeneOne Life Science
  • GlaxoSmithKline (GSK) plc
  • Johnson & Johnson Services, Inc.
  • Medigen Vaccine Biologics
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi Pasteur
  • Serum Institute of India
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Vabiotech

Related Topics

Related Reports

Dengue Vaccine - Global Strategic Business Report - Product Image

Dengue Vaccine - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Dengue Vaccines Market Outlook 2026-2034: Market Share, and Growth Analysis by Vaccine Type (Live-attenuated recombinant (CYD-TDV), Live-attenuated chimeric (TAK-003), DNA Vaccines, Inactivated Vaccines, Subunit / VLP Vaccines), End User, Distribution Channel - Product Image

Dengue Vaccines Market Outlook 2026-2034: Market Share, and Growth Analysis by Vaccine Type (Live-attenuated recombinant (CYD-TDV), Live-attenuated chimeric (TAK-003), DNA Vaccines, Inactivated Vaccines, Subunit / VLP Vaccines), End User, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Dengue Vaccine Market Report 2026 - Product Image

Dengue Vaccine Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Vaccines Market - Global Forecast 2026-2032 - Product Image

Vaccines Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Vaccine Adjuvants Market - Global Forecast 2026-2032 - Product Image

Vaccine Adjuvants Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From

About the Dengue Vaccine Market

The Dengue Vaccine market is a subset of the larger Vaccines market. Dengue is a mosquito-borne virus that can cause severe flu-like symptoms and can be fatal in some cases. Vaccines are the most effective way to prevent dengue infection. The Dengue Vaccine market is composed of a variety of products, including live attenuated vaccines, inactivated vaccines, and recombinant vaccines. These products are used to protect against all four serotypes of the dengue virus. The Dengue Vaccine market is highly competitive, with many companies vying for market share. Companies in the market include Sanofi Pasteur, Merck, GlaxoSmithKline, Takeda, and Bharat Biotech. These companies are actively developing and marketing dengue vaccines to meet the growing demand for protection against the virus. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.